Skip to main content
SpringerLink
Log in

Current Status and Perspectives of Pharmacotherapeutic Research Related to Schizophrenic Psychoses

  • Conference paper
Schizophrenia and Youth

  • 132 Accesses

Abstract

Neuroleptics have now been available for antipsychotic treatment over more than 35 years. During this period valuable information has been obtained on the mechanism of action of neuroleptic drugs, on the relation between altered behavior and neurotransmission, and on the pathophysiology of schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anden N-E (1972) Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol 24: 905–906

    Article  PubMed  CAS  Google Scholar 

  • Anden N-E, Carlsson A, Dahlstrom D, Fuxe K, Millarp N-A, Larsson K (1964) Demonstration and mapping out of nigroneostriatal dopamine neurons. Life Sci 3: 523–530

    Article  PubMed  CAS  Google Scholar 

  • Ansoms C, de Backer-Dierick C, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression. Double-blind placebo controlled evaluation of the value of pipamperone ( Dipiperon ). Acta Psychiatr Scand 55: 116–122

    Google Scholar 

  • Auff E, Birkmayer W, Brücke T, Deecke L, Emich C, Goldenberg G, Hirsch E, Maly J, Müller C, Pötal G, Riederer P, Sofic E, Schnaberth G (1987) Ritanserin in the treatment of tremor-dominant Parkinson’s disease: a preliminary study. New Trends Clin Neuropharmacol 1: 149–158

    Google Scholar 

  • Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific serotonin S2 antagonist. Drug Dev Res 15: 61–73

    Article  CAS  Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40: 492–499

    Google Scholar 

  • Bersani G, Bressa GM, Meco G, Marini S, Pozzi F (1990) Combined serotonin 5-HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64766). Hum Psychopharmacol (Berlin) 5: 225–231

    Article  Google Scholar 

  • Brown JH, Makman M (1972) Stimulation by dopamine of adenylate cyclase in retinal homogenates and of adenosine 3’S’ cyclic monophosphate formation in intact retina. Proc Natl Acad Sci USA 69: 539–543

    Article  PubMed  CAS  Google Scholar 

  • Burt DR, Creese I, Snyder SH (1976) Properties of [3H]-haloperidol binding and (3H)-dopamine binding associated with dopamine receptors in calf membranes. Mol Pharmacol 12: 800–812

    PubMed  CAS  Google Scholar 

  • Carlsson A (1975) Dopaminergic autoreceptors. In: Almgren O, Carlsson A, Engel J (eds) Chemical tools in catecholamine research, vol 2. North-Holland, Amsterdam, pp 219–224

    Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20: 140–144

    Article  CAS  Google Scholar 

  • Castelao JF, Ferreira L, Gelders YG, Heylen SLE (1989) The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res 2: 411–415

    Google Scholar 

  • Ceulemans DLS, Hoppenbrouwers M-LJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders; a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303–305

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Chen TY, Wu HS, Hu WH, Yeh EK (1988) Dose response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies. Psychopharmacology (Berlin) 95: 459–462

    Article  CAS  Google Scholar 

  • Colpaert FC, Niemegeers CJE, Janssen PAJ (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. J. Pharmacol Exp Ther 221: 206–214

    PubMed  CAS  Google Scholar 

  • Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ (1985) Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats. Psychopharmacology (Berlin) 86: 45–54

    Article  CAS  Google Scholar 

  • Coppen A, Prange AJ, Whybrow PC, Noguera R, Paez JM (1969) Methysergide in mania. A controlled trial. Lancet 2: 338–340

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1975) Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sci 17: 993–1002

    Article  CAS  Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483

    Article  PubMed  CAS  Google Scholar 

  • Critchley MAE, Handley SE (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berlin) 93: 502–506

    Article  CAS  Google Scholar 

  • Crow TJ, Deakin JFW, Longden A (1977) The nucleus accumbens — possible site of antipsychotic action of neuroleptic drugs. Psychol Med 7: 213–221

    Article  PubMed  CAS  Google Scholar 

  • Deberdt R (1976) Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation. Acta Psychiatr Belg 76: 157–166

    PubMed  CAS  Google Scholar 

  • Declerck AC, Wauquier A, van der Haes-Veltman PHM, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin S2 antagonist ritanserin. Curr Ther Res 41: 427–432

    Google Scholar 

  • De Cuyper HJA (1989) Risperidone in the treatment of chronic psychotic patients: an overview of the double-blind comparative studies. In: Ayd FJ (ed) 30 years Janssen Research in Psychiatry. Ayd Medical Communications, Baltimore, pp 115–122

    Google Scholar 

  • Dewhurst WG (1968) Methysergide in mania. Nature 219: 506–507

    Article  PubMed  CAS  Google Scholar 

  • Dugovic C, Wauquier A (1987) 5-HT2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 137: 145–146

    Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Wiesel FA, Nordström AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berlin) 99: S28 - S31

    Article  Google Scholar 

  • Fischer-Cornelssen KA, Ferner U (1976) An example of European multicenter trials (multispectral analysis of clozapine). Psychopharmacol Bull 12: 34–39

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Miller CH, Ehrmann H (1990) Ritanserin in the treatment of neuroleptic-induced akathesia. Schizophr Res 3: 47

    Article  Google Scholar 

  • Gallant DM, Bishop MP (1968) Cinanserin (Sch 10643): a preliminary evaluation in chronic schizophrenic patients. Curr Ther Res 10: 461–463

    PubMed  CAS  Google Scholar 

  • Gallant DM, Bishop MP, Steele CA, Noblin CD (1963) The relationship between serotonin antagonism and tranquillizing activity. Am J Psychiatry 119: 882

    PubMed  CAS  Google Scholar 

  • Gelders Y, vanden Bussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol [Suppl 4] 9: 325–327

    Google Scholar 

  • Gelders YE, Heylen SLE, vanden Bussche G, Reyntjens AJM, Janssen PAJ (1989) Risperidone, a breakthrough in antipsychotic therapy. In. Ayd FJ (ed) 30 years Janssen Research in Psychiatry. Ayd Medical Communications, Baltimore, pp 123–128

    Google Scholar 

  • Guyenet PG, Agid Y, Javoy F, Beaujouan JC, Rossier J, Glowinski J (1975) Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system. Brain Res 84: 227–244

    Article  PubMed  CAS  Google Scholar 

  • Haskovec L, Soucek K (1968) Trial of methysergide in mania. Nature 219: 507–508

    Article  PubMed  CAS  Google Scholar 

  • Hildebrand J, Delecluse F (1987) Effect of ritanserin, a selective serotonin S2 antagonist in Parkinsonian rest tremor. Curr Pharm Res 41: 298–350

    Google Scholar 

  • Hjorth SA, Carlsson A, Wikström H, Lindberg P, Sanchez D, Hacksell W, Arvidsson L-E, Svensson U, Nilsson JLC (1981) 3 PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28: 1225–1238

    Google Scholar 

  • Hjorth SA, Carlsson A, Clark D, Svensson K, Wikström H, Sanchez D, Lindberg P, Hacksell Y, Arvidsson LE, Johannsson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist action of the enantiomers of 3PPP. Psychopharmacology (Berlin) 81: 89–99

    Article  CAS  Google Scholar 

  • Holden JMC, Itil T, Keskiner A, Gannon P (1971) A clinical trial of an antiserotonin compound, cinanserin, in chronic schizophrenia. J Clin Pharmacol 11: 220–226

    CAS  Google Scholar 

  • Hyttel J (1983) SCH 23390, the first selective dopamine-D1 antagonist. Eur J Pharmacol 91: 153–154

    Article  PubMed  CAS  Google Scholar 

  • Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytyptamine-2-antagonist increases human slow waves sleep. Brain Res 378: 164–168

    Article  PubMed  CAS  Google Scholar 

  • Idzikowski C, Cowen PJ, Nutt D, Mills FJ (1987) The effect of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology (Berlin) 93: 416–420

    Article  CAS  Google Scholar 

  • Iversen LL (1975) Dopamine receptors in the brain. A dopamine-sensitive adenylate cyclase models synaptic receptors, illuminating antipsychotic drug action. Science 188: 1084–1089

    Article  PubMed  CAS  Google Scholar 

  • Janssen PAJ (1987a) Does ritanserin, a potent serotonin S2 antagonist, restore energetic functions during the night. J R Soc Med 80: 409–413

    PubMed  CAS  Google Scholar 

  • Janssen PAJ (1987b) The development of new antipsychotic drugs: towards a new strategy in the management of chronic psychoses. J Drug Ther Res 12: 324–328

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? I. Neuroleptic activity spectra for rats. Arzneimittel Forschung 15: 104–117

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693

    PubMed  CAS  Google Scholar 

  • Kebabian JW, Petzold GL, Greengard P (1972) Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the “dopamine receptor”. Proc Natl Acad Sci USA 69: 2145–2149

    Article  PubMed  CAS  Google Scholar 

  • Köhler C, Haglund L, Ogren SDO, Ängeby T (1981) Regional blockade by neuroleptic drugs of “in vivo” 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity. J Neural Transm 52: 163–173

    Google Scholar 

  • Laduron P, Leysen J (1977) Specific in vivo binding of neuroleptic drugs in rat brain. Biochem Pharmacol 26: 1003–1007

    Article  PubMed  CAS  Google Scholar 

  • Le Fur G, Guilloux F, Uzan A (1980) In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics. Biochem. Pharmacol 29: 267–270

    Google Scholar 

  • Leysen JE, Laduron PM (1977a) Differential distribution of opiate and neuroleptic receptors and dopamine-sensitive adenylate cyclase in rat brain. Life Sci 20: 281–288

    Article  PubMed  CAS  Google Scholar 

  • Leysen JE, Laduron PM (1977b) A serotonergic component of neuroleptic receptors. Arch Int Pharmacol Ther 230: 337–339

    CAS  Google Scholar 

  • Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry, vol 9. Plenum, New York, pp 331–361

    Google Scholar 

  • Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin. Neuropharmacol 9: 480–484

    Google Scholar 

  • Maire FW, Collins LG, Marks JB (1967) Evaluation of the drug 1-methyl-d-lysergic acid butanolamide or methysergide maleate in the treatment of chronic schizophrenia. Int J Neurophysiol 3: 397–399

    CAS  Google Scholar 

  • Meco G, Marini S, Lestingi L, Linfante I, Modarelli FT, Agnoli A (1988) Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson’s disease. Curr Ther Res 43: 262–270

    Google Scholar 

  • Meco G, Bedini L, Bonifati V, Sonsini U (1989) Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 46: 876–883

    Google Scholar 

  • Meert TF (1986) A comparative study of the effects of ritanserin (R 55667) and chlordiazepoxide on rat open field behavior. Drug Dev Res 8: 197–204

    Article  CAS  Google Scholar 

  • Mendels J (1967) The effect of methysergide (an antiserotonin agent) on schizophrenia: a preliminary report. Am J Psychiatry 124: 849–852

    PubMed  CAS  Google Scholar 

  • Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychiatric patients. Psychopharmacology (Berlin) 99: 445–449

    Article  CAS  Google Scholar 

  • Niemegeers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216

    Article  PubMed  CAS  Google Scholar 

  • Pangalila-Ratu Langi EA, Jansen AAI (1988) Ritanserin in the treatment of generalized anxiety disorders: a placebo-controlled trial. Hum Psychopharmacol 3: 207–212

    Article  Google Scholar 

  • Persyko I (1972) Psychiatric adverse reaction to methysergide. J Nery Ment Dis 154: 299–301

    Article  CAS  Google Scholar 

  • Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, vanden Bussche G (1986) Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin S2 receptor blocker. Drug Dev Res 8: 205–211

    Article  CAS  Google Scholar 

  • Roose K, Gelders Y, Heylen S (1988) Risperidone (R 64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg 88: 233–241

    PubMed  CAS  Google Scholar 

  • Seeman P (1977) Anti-schizophrenic drugs — membrane receptor sites of action. Biochem Pharmacol 26: 1741–1748

    Article  PubMed  CAS  Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313

    PubMed  CAS  Google Scholar 

  • Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72: 4376–4380

    Article  PubMed  CAS  Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719

    Article  PubMed  CAS  Google Scholar 

  • Squelart P, Saravia J (1977) Pipamperone ( Dipiperon), a useful sedative neuroleptic drug in troublesome and chronic psychotic patients. Acta Psychiatr Belg 77: 284–293

    Google Scholar 

  • Stadler H, Lloyd KG, Gadea-Ciria M, Batholini G (1973) Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res 55: 476–480

    Article  PubMed  CAS  Google Scholar 

  • Stamford JA, Kruk LL, Millar J (1988) Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study. Br J Pharmacol 94: 924–932

    Article  PubMed  CAS  Google Scholar 

  • Stevens JR (1973) An antomy of schizophrenia? Arch Gen Psychiatry 29: 177–189

    Article  PubMed  CAS  Google Scholar 

  • Ungerstedt U (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand [Suppl. 367] 82: 1–48

    Article  Google Scholar 

  • Woolley DW (1962) The biochemical bases of psychoses, on the serotonin hypothesis about mental diseases. Wiley, New York, pp 131–192

    Google Scholar 

Download references

Authors
  1. C. J. E. Niemegeers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Awouters
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendpsychiatrie, Rheinische Landes- u. Hochschulklinik, Hufelandstraße 55, 4300, Essen, Germany

    Christian Eggers (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Niemegeers, C.J.E., Awouters, F. (1991). Current Status and Perspectives of Pharmacotherapeutic Research Related to Schizophrenic Psychoses. In: Eggers, C. (eds) Schizophrenia and Youth. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-02684-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-02684-7_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52485-4

  • Online ISBN: 978-3-662-02684-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation